Dimerix Says IDMC Found No Safety Concerns in Phase Three Kidney Disease Trial

MT Newswires Live

Nov 19, 2025

Dimerix (ASX:DXB) said the Independent Data Monitoring Committee (IDMC) completed a seventh review of the Action3 phase three clinical trial safety data, raising no safety concerns and recommending the continuation of the trial, according to a Wednesday filing with the Australian bourse.

The trial is evaluating the safety and efficacy of drug candidate DMX-200 in patients with the kidney disease focal segmental glomerulosclerosis.

The next IDMC meeting is planned for the second quarter of 2026, the filing said.

Shares rose 2% in afternoon trade on Wednesday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2584999337"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2584999337\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2584999337?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-19 11:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584999337","market":"nz","top_or_hot":-1,"title":"Dimerix Says IDMC Found No Safety Concerns in Phase Three Kidney Disease Trial","media":"MT Newswires Live","content":"<html><body><p> Dimerix (ASX:DXB) said the Independent Data Monitoring Committee (IDMC) completed a seventh review of the Action3 phase three clinical trial safety data, raising no safety concerns and recommending the continuation of the trial, according to a Wednesday filing with the Australian bourse.</p><p>The trial is evaluating the safety and efficacy of drug candidate DMX-200 in patients with the kidney disease focal segmental glomerulosclerosis.</p><p>The next IDMC meeting is planned for the second quarter of 2026, the filing said.</p><p>Shares rose 2% in afternoon trade on Wednesday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dimerix Says IDMC Found No Safety Concerns in Phase Three Kidney Disease Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDimerix Says IDMC Found No Safety Concerns in Phase Three Kidney Disease Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-11-19 11:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Dimerix (ASX:DXB) said the Independent Data Monitoring Committee (IDMC) completed a seventh review of the Action3 phase three clinical trial safety data, raising no safety concerns and recommending the continuation of the trial, according to a Wednesday filing with the Australian bourse.</p><p>The trial is evaluating the safety and efficacy of drug candidate DMX-200 in patients with the kidney disease focal segmental glomerulosclerosis.</p><p>The next IDMC meeting is planned for the second quarter of 2026, the filing said.</p><p>Shares rose 2% in afternoon trade on Wednesday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DXB.AU","symbol_name":"DIMERIX LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2584999337","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584999337","pubTimestamp":1763521785,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Dimerix (ASX:DXB) said the Independent Data Monitoring Committee (IDMC) completed a seventh review of the Action3 phase three clinical trial safety data, raising no safety concerns and recommending th","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"DXB.AU":"DIMERIX LTD","BK7067":"生物科技","BK7508":"医药生物股","BK7501":"新冠治疗股"},"translate_title":"Dimerix表示IDMC在三期肾病试验中未发现安全问题","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DXB.AU":1},"content_text":"Dimerix (ASX:DXB) said the Independent Data Monitoring Committee (IDMC) completed a seventh review of the Action3 phase three clinical trial safety data, raising no safety concerns and recommending the continuation of the trial, according to a Wednesday filing with the Australian bourse.The trial is evaluating the safety and efficacy of drug candidate DMX-200 in patients with the kidney disease focal segmental glomerulosclerosis.The next IDMC meeting is planned for the second quarter of 2026, the filing said.Shares rose 2% in afternoon trade on Wednesday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}